Multiple GWAS and subsequent meta-analyses consistently report the H1 and H2 MAPT haplotypes to be over and under-represented, respectively, in PD, PSP and CBD [13–15], demonstrating the genetic risk and protection contributed by the H1 and H2 polymorphisms. This evidence concerns the gene MAPT and Parkinson disease.